ALPHAGAN P SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

BRIMONIDINE TARTRATE

제공처:

ABBVIE CORPORATION

ATC 코드:

S01EA05

INN (International Name):

BRIMONIDINE

복용량:

0.15%

약제 형태:

SOLUTION

구성:

BRIMONIDINE TARTRATE 0.15%

관리 경로:

OPHTHALMIC

패키지 단위:

3/5/10ML

처방전 유형:

Prescription

치료 영역:

ALPHA-ADRENERGIC AGONISTS

제품 요약:

Active ingredient group (AIG) number: 0131859003; AHFS:

승인 상태:

APPROVED

승인 날짜:

2003-11-04

제품 특성 요약

_ALPHAGAN P (brimonidine tartrate) _
_Page 1 of 26 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ALPHAGAN P®
brimonidine tartrate ophthalmic solution
Solution, 0.15% w/v, for ophthalmic use
Relatively Selective α
2
-Adrenoceptor Agonist
ATC code: S01EA05
AbbVie Corporation
8401 Trans-Canada Highway
St-Laurent, Quebec
H4S 1Z1
Submission Control Number: 266495
Date of Initial Authorization:
NOV 04, 2003
Date of Revision:
AUG
25, 2022
_ALPHAGAN P (brimonidine tartrate) _
_Page 2 of 26 _
RECENT MAJOR LABEL CHANGES
None at the time of the most recent authorization.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics
..................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
................................................................................
4
4.1
Dosing Considerations
.............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
........................................................ 4
4.4
Administration
.........................................................................................................
5
4.5
Missed Dose
...